Medical Applications of Non-Porous Silica Nanoparticles Development of Non-Porous Silica Nanoparticles towards Cancer Photo-Theranostics
Chihiro Mochizuki 1,2, Junna Nakamura 1,2 and Michihiro Nakamura 1,2,*
Published: Jan 13, 2021 (biomedicines)
Study Conclusions and Future Perspectives...
Among various biomedical nanoparticles, including mesoporous silica nanoparticles, non-porous silica nanoparticles have demonstrated high potential for the realization of “photo-theranostic” techniques. Currently, non-porous silica nanoparticles are being actively developed for clinical applications. C dots have received approval from the U.S. Food and Drug Administration (FDA) for their first-in-human clinical trial as cancer- specific probes. The clinical trial revealed the effectiveness and safety of C dots as hybrid PET-optical imaging agents [156,180].
In addition, AGuIX® nanoparticles made of silica and gadolinium have been developed as novel theranostics radiosensitizing nanoparticles. AGuIX® has been accepted in clinical trials and is undergoing testing [181–185]. As an FDA-approved silica material, TheraSphere has been accepted for the selective internal radiation therapy of primary and metastatic hepatic malignancies [186–191]. These nano- and micro-sized clinically translated particles are non-porous, dense sil- ica particles. Therefore, silica nanoparticles are highly promising materials in clinically translational “photo-theranostics”.
Using silica nanoparticles also shows early/preclinical promise in transmucosal drug delivery (method of improving drug adhesion/retention & more sustained drug release) for a variety of diseases, including type 2 diabetes, inflammatory bowel disease, neurodegenerative diseases & cancer...an in vitro model for bladder cancer via intravesical delivery looks very promising.
Just a little more promising pharmacokinetic/tox data is needed, then the incredible potential in nanosilicon gets unleashed imo. GLTA.